Christopher Nolan, Odyssey and Oppenheimer

Oppenheimer initiated coverage of Alumis (ALMS) with an Outperform rating and $32 price target The company is focused on delivering ...
British consumers’ appetite for home entertainment reached new heights in 2024, with the sector surpassing £5.1 billion ($6.4 ...
Shares of Apple have surged roughly 40% over the past nine months, but one analyst issued a cautious warning that it’s time to tap the brakes ahead of the company’s earnings report set for Thursday.
(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...
U.S. filmmaker Joshua Oppenheimer, now based in Denmark, worries his "home country is perhaps becoming a dictatorship." "It ...
Amid the financial shock waves being sent by the release of DeepSeek's open source artificial intelligence R1 model, ...
Within financials ( XLF ), Wald mentioned capital markets and the SPDR S&P Capital Markets ETF ( KCE) as a top idea, ...
Oppenheimer upgraded Ovid Therapeutics (OVID) to Outperform from Perform with a $4 price target The firm says OV329’s promise is “quite real” ...